Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod cream effect on atrial ectopy in AK
NCT01413763Phase 4Unknown
- Sponsor
- Medicis Pharmaceutical
- Start
- Jul 2011
- Primary completion
- Apr 2013
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of imiquimod in actinic keratosis (AK) (2 arms), sponsored by Medicis Pharmaceutical. Primary endpoint: Change in 24-hour supraventricular premature beat count at Day 14. Status: unknown.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01413763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01413763.